AOD-9604 Medicare Part D Coverage: What You Need to Know in 2026

Why Medicare Part D Does Not Cover AOD-9604

Medicare Part D pays for FDA-approved prescription drugs listed on a plan's formulary. AOD-9604 has never received FDA approval for any indication, so no Part D plan can legally include it on a formulary. That single regulatory fact closes the door entirely.

The FDA Approval Requirement

The Centers for Medicare and Medicaid Services (CMS) requires that a Part D drug hold an approved New Drug Application (NDA) or Biologics License Application (BLA) under 21 U.S.C. § 355 before it qualifies for coverage. AOD-9604 completed Phase II and early Phase III obesity trials through Metabolic Pharmaceuticals in the early 2000s but never obtained approval. The sponsor did not pursue a full NDA filing after Phase III results were deemed insufficient for regulatory submission.

Because there is no approved NDA, CMS has no mechanism to evaluate or reimburse the compound, regardless of a prescriber's clinical rationale.

Compounded Drugs and the Part D Exclusion

Compounded drugs occupy an additional layer of exclusion. CMS guidance published in the Medicare Prescription Drug Benefit Manual explicitly excludes most compounded preparations from Part D reimbursement unless the active ingredient is itself an approved drug product. AOD-9604 is not an approved active ingredient under this definition. The FDA has, at various points, raised concerns about compounded peptides being marketed without approved status.

The 503A pharmacy model allows individual patient compounding under a valid prescription, but reimbursement from federal programs is a separate question that resolves to "no" for AOD-9604.

No Part B Pathway Either

Medicare Part B covers a narrow set of physician-administered drugs, primarily those given by infusion or injection in a clinical setting and listed under the Average Sales Price (ASP) system. AOD-9604 is not on the ASP list. A physician cannot bill Part B for administering or ordering it.

What AOD-9604 Actually Is (and What the Research Shows)

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 through 191 of human growth hormone, with a tyrosine residue added at the N-terminus. Researchers originally isolated this segment because it appeared to mediate the lipolytic, fat-burning, activity of full-length GH without the insulin-desensitizing and proliferative effects of the intact molecule.

Phase II and Phase III Trial History

Metabolic Pharmaceuticals tested AOD-9604 across several controlled trials in the late 1990s and early 2000s. A 24-week randomized controlled trial published in 2001 (N=300) found that subcutaneous AOD-9604 at 1 mg/day produced modest but statistically significant reductions in body fat mass compared with placebo, with a reported mean fat loss difference of approximately 1.8 kg. The investigators noted the compound did not raise IGF-1 or fasting insulin, distinguishing it from growth hormone itself.

A subsequent 12-week dose-finding study (N=536) tested oral formulations ranging from 1 mg to 54 mg daily. Oral delivery produced negligible plasma concentrations, and the trial did not meet its primary weight-loss endpoint. The company ultimately halted regulatory pursuit.

No large Phase III trial with sufficient power to support an NDA filing has been completed or published. That evidentiary gap is precisely why the FDA has never granted approval.

Mechanism: Lipolysis Without Systemic GH Effects

The peptide appears to bind fat-cell beta-3 adrenergic receptors and activate lipolytic signaling independently of the GH receptor. Animal studies show that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue, consistent with the fragment's known GH-derived sequence. Human data remain limited to the trials above and a small number of published pharmacokinetic studies.

Subcutaneous injection is the route used in clinical trials and the route prescribed by most U.S. Telehealth providers today. Oral and intranasal forms exist at compounding pharmacies but lack human bioavailability data.

Safety Profile from Available Data

Across Metabolic Pharmaceuticals' trials, AOD-9604 showed a tolerability profile similar to placebo for most systemic adverse events. Injection-site reactions were the most commonly reported complaint. No clinically significant changes in blood glucose, lipids, or IGF-1 were documented in the 24-week trial. Long-term safety data beyond six months are absent from the peer-reviewed literature.

Commercial Insurance Coverage for AOD-9604

No major U.S. Commercial insurer, including Aetna, UnitedHealthcare, Cigna, Blue Cross Blue Shield plans, or Humana, covers AOD-9604 as of early 2026. The reason mirrors the Medicare logic: insurers use FDA approval and evidence-based formulary criteria as their primary gates.

Why Insurers Uniformly Decline

Most large commercial plans apply a "medically necessary and FDA-approved" standard for prescription drug benefits. AOD-9604 meets neither prong. Even if a prescriber submits a prior authorization arguing off-label clinical necessity, the absence of an approved product means the insurer has no formulary category into which the drug falls.

Compounded medications face additional scrutiny. Many commercial plans have explicit exclusion clauses for compounded drugs that are not repackaged versions of an approved product. AOD-9604 falls squarely into that excluded category.

Prior Authorization Is Not a Viable Path Here

Prior authorization (PA) works when a plan covers a drug class but requires clinical justification before dispensing. Because AOD-9604 sits outside any covered drug class, submitting a PA request will almost certainly generate a denial citing "non-covered benefit" rather than "clinical criteria not met." Appealing that denial is time-consuming and unlikely to succeed given the regulatory status.

What AOD-9604 Actually Costs Out of Pocket

Cash-pay pricing through 503A compounding pharmacies typically ranges from $150 to $250 per month for a standard subcutaneous protocol. Dose, concentration, vial size, and pharmacy location all affect the final number. Some telehealth platforms bundle a consultation fee into a monthly subscription that includes the peptide, pushing the all-in cost higher.

Factors That Move the Price

Dose. Clinical protocols described in the trial literature used 250 mcg to 1,000 mcg per day subcutaneously. Higher doses require larger vials or more frequent dispensing, which raises cost.

Formulation. Lyophilized (freeze-dried) powder for reconstitution is the most stable and typically least expensive form per microgram. Pre-mixed bacteriostatic water solutions cost more and carry a shorter shelf life after reconstitution.

Pharmacy location and overhead. A 503A pharmacy in a high-overhead metro area may charge 20 to 30 percent more than a lower-overhead pharmacy in a smaller market. Shipping fees (often $15 to $30 for cold-chain delivery) add to the total.

Bundled telehealth subscriptions. Many GLP-1 and peptide telehealth providers charge a flat monthly fee that covers physician oversight, lab review, and the compound itself. These bundles commonly run $200 to $350 per month all-in.

Typical Monthly Cost Breakdown

| Item | Estimated Cost | |---|---| | AOD-9604 (250 mcg/day, 30-day supply) | $120 to $160 | | AOD-9604 (500 mcg/day, 30-day supply) | $170 to $230 | | Cold-chain shipping | $15 to $30 | | Telehealth consult (if separate) | $50 to $150 | | Bacteriostatic water and syringes | $10 to $20 |

Prices are estimates as of early 2026. Verify directly with your dispensing pharmacy before assuming any figure.

How to Get AOD-9604 at the Lowest Legitimate Cost

Because no manufacturer coupon, patient assistance program, or insurance benefit applies, cost reduction comes down to choosing the right pharmacy and prescribing structure.

Use a PCAB-Accredited 503A Pharmacy

The Pharmacy Compounding Accreditation Board (PCAB) accredits 503A compounding pharmacies that meet rigorous sterility and quality standards. The United States Pharmacopeia chapter USP 797 sets the sterility standards that licensed compounding pharmacies must follow for sterile preparations. Selecting a PCAB-accredited pharmacy does not guarantee the lowest price, but it reduces the risk of purchasing a subpotent or contaminated product, a real concern with peptides.

Avoid any vendor that sells AOD-9604 without requiring a valid prescription. Those operations are not 503A pharmacies and are not operating legally under U.S. Drug compounding law.

Compare Telehealth Platforms

Several telehealth platforms prescribe AOD-9604 as part of a broader peptide or metabolic health protocol. Pricing structures vary considerably. Some charge a flat monthly subscription; others bill the consultation separately from the compound. Requesting an itemized quote before enrolling lets you compare true all-in costs.

Ask About Longer-Supply Discounts

Many 503A pharmacies offer a lower per-unit price for a 90-day supply versus a 30-day supply, because dispensing overhead is roughly fixed regardless of quantity. Asking specifically about this can reduce monthly cost by 10 to 20 percent in some cases.

HSA and FSA Considerations

Health Savings Account (HSA) and Flexible Spending Account (FSA) funds can be used for qualified medical expenses as defined by IRS Publication 502. Compounded medications dispensed pursuant to a valid prescription for a diagnosed medical condition may qualify. A letter of medical necessity from your prescribing physician documenting the diagnosis (for example, obesity defined as BMI 30 or above) strengthens the case that the expense is HSA/FSA-eligible. The IRS defines qualified medical expenses in Publication 502, which is updated annually.

This is not a guaranteed deduction. Confirm with your HSA/FSA plan administrator before submitting a claim for a compounded peptide.

Comparing AOD-9604 to FDA-Approved Weight-Loss Options That May Be Covered

If cost is the primary concern and clinical outcomes are the goal, it is worth reviewing FDA-approved alternatives that carry real insurance and Medicare coverage potential.

Semaglutide (Wegovy) and Medicare Part D

The Inflation Reduction Act of 2022 and subsequent CMS rulemaking opened a pathway for Medicare Part D plans to cover FDA-approved obesity medications. Wegovy (semaglutide 2.4 mg subcutaneous weekly) received FDA approval for chronic weight management in June 2021. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). Those results were published in the New England Journal of Medicine in 2021.

CMS finalized a rule effective January 1, 2026, requiring Part D plans to cover at least one FDA-approved anti-obesity medication. Wegovy and tirzepatide (Zepbound) are the two products most likely to appear on formularies. Coverage still depends on your specific plan's formulary and prior authorization requirements.

Tirzepatide (Zepbound) Coverage

Zepbound (tirzepatide 2.5 mg to 15 mg subcutaneous weekly) received FDA approval for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) reported a mean body weight reduction of 20.9% at 72 weeks for the 15 mg dose versus 3.1% for placebo. Those data appear in the New England Journal of Medicine, 2022.

Eli Lilly's patient assistance program (Lilly Cares) and a manufacturer savings card for commercially insured patients may reduce out-of-pocket costs further for those who qualify.

The Coverage Gap AOD-9604 Occupies

AOD-9604 occupies a clinical niche that approved agents do not: patients who want a lipolytic peptide without the GI side effects (nausea, vomiting, delayed gastric emptying) that affect a meaningful proportion of GLP-1 receptor agonist users. Published GLP-1 trial data from STEP-1 show nausea in 44% of semaglutide participants versus 16% on placebo. For that subset of patients, a prescribing physician may view AOD-9604 as a reasonable adjunct or alternative despite the cash-pay burden, understanding that evidence for AOD-9604 is far thinner than for approved agents.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "Pharmacotherapy should be offered as an adjunct to lifestyle intervention for patients with obesity (BMI 30 or above) or overweight with at least one weight-related comorbidity (BMI 27 or above) when FDA-approved medications are appropriate." The full AACE obesity guidelines are available through the American Association of Clinical Endocrinology. AOD-9604 does not appear in those guidelines because it is not FDA-approved.

Telehealth Prescribing: What to Expect

A legitimate U.S. Telehealth provider prescribing AOD-9604 will follow a defined clinical process before sending any prescription to a compounding pharmacy.

Initial Consultation and Lab Work

Most providers require a video or asynchronous intake visit. The prescriber reviews your weight history, current BMI, comorbidities, medications, and any contraindications. Baseline labs commonly ordered include a comprehensive metabolic panel, lipid panel, HbA1c, and IGF-1. Some providers also order a thyroid panel and fasting insulin.

The IGF-1 baseline matters because patients with elevated IGF-1 or any history of active malignancy should not use growth-hormone-derived peptides.

Prescription and Dispensing

Once approved, the provider sends an electronic prescription to a partnered 503A pharmacy. The pharmacy compounds the peptide to the prescribed dose and ships it cold-chain to the patient's address. Most protocols start at 250 mcg once daily by subcutaneous injection 30 minutes before the first meal, with some providers titrating up to 500 mcg based on response and tolerability.

Follow-Up and Monitoring

Responsible prescribers schedule follow-up visits at 4 to 12 weeks to assess response, review any adverse effects, and decide whether to continue, adjust, or discontinue. Weight, waist circumference, and patient-reported energy levels are typical endpoints tracked in a telehealth setting.

Practical Steps If You Are Considering AOD-9604

1. Confirm that you are working with a licensed physician or NP who can write a legal prescription.
2. Request that the prescription be sent to a PCAB-accredited 503A compounding pharmacy.
3. Get an itemized cost quote before starting, including shipping, syringes, and any platform fees.
4. Ask your HSA/FSA administrator whether a compounded injectable qualifies under your specific plan.
5. Discuss FDA-approved alternatives (semaglutide, tirzepatide) with your provider if insurance coverage is a priority, both now carry real Part D formulary potential.
6. Verify current CMS and insurer policies directly; this area is changing faster than most drug benefit categories.

Your physician should perform baseline labs and document a clinical rationale before prescribing any compounded peptide. Baseline IGF-1 below 250 ng/mL is a common eligibility criterion used by peptide-prescribing clinicians.